Lv1
90 积分 2024-02-28 加入
Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond
3天前
已完结
Consistent Estimation of the Expected Brier Score in General Survival Models with Right‐Censored Event Times
3天前
已完结
On the C‐statistics for evaluating overall adequacy of risk prediction procedures with censored survival data
3天前
已完结
Combining EBV DNA dynamics with RECIST-based radiographic response to improve prognostic stratification of recurrent/metastatic nasopharyngeal carcinoma in the era of immunotherapy
15天前
已关闭
CompARE: study protocol for a phase III randomised controlled platform trial comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer
2个月前
已关闭
Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial
2个月前
已完结
Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial
2个月前
已完结
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
2个月前
已完结
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial
2个月前
已完结
1319O Perioperative camrelizumab plus chemotherapy in locally advanced squamous cell carcinoma of the head and neck (CAMORAL): A multicenter, open-label, randomized, phase II Study
2个月前
已关闭
皖公网安备34019202002308
